Evaxion Biotech (Nasdaq:EVAX) - Hisse Senedi Fiyatı, Haberler ve Analizler

EVAX Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Evaxion Biotech A/S, yapay zekâ destekli immünoterapiler geliştirmektedir.

Şirket hakkında

EVAX temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Earnings are forecast to grow 69.87% per year

Trading at good value compared to peers and industry

Risk Analizi

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Does not have a meaningful market cap ($14M)

Does not have meaningful revenue ($3M)

+ 1 daha fazla risk

Evaxion Biotech A/S Rakipler

bioAffinity Technologies

NasdaqCM:BIAF

US$18.5m

Onconetix

NasdaqCM:ONCO

US$24.1m

Tonix Pharmaceuticals Holding

NasdaqCM:TNXP

US$24.9m

Eterna Therapeutics

NasdaqCM:ERNA

US$5.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Evaxion Biotech
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.59
52 Haftanın En Yüksek Seviyesi	US$13.61
52 Haftanın En Düşük Seviyesi	US$2.26
Beta	-0.25
11 Aylık Değişim	-12.20%
3 Aylık Değişim	-7.04%
1 Yıllık Değişim	-76.67%
33 Yıllık Değişim	-96.23%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-97.38%

Son Haberler & Güncellemeler

Recent updates

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Mar 31

Evaxion Biotech names Per Norlén as CEO

Oct 05

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform

Jun 03

Hissedar Getirileri

	EVAX	US Biotechs	US Pazar
7D	-8.8%	-0.7%	-1.6%
1Y	-76.7%	19.8%	30.8%

Getiri vs. Endüstri: EVAX underperformed the US Biotechs industry which returned 19.8% over the past year.

Getiri vs Piyasa: EVAX underperformed the US Market which returned 30.8% over the past year.

Fiyat Oynaklığı

Is EVAX's price volatile compared to industry and market?
EVAX volatility
EVAX Average Weekly Movement	11.7%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: EVAX's share price has been volatile over the past 3 months compared to the US market.

Zaman İçindeki Volatilite: EVAX's weekly volatility has decreased from 23% to 12% over the past year, but is still higher than 75% of US stocks.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2008	49	Christian Kanstrup	www.evaxion-biotech.com

Klinik aşamada bir biyoteknoloji şirketi olan Evaxion Biotech A/S, yapay zekâ destekli immünoterapiler geliştirmektedir. Şirket, metastatik melanom tedavisi için faz 2 küresel çok merkezli klinik çalışmada olan EVX-01'i; rezeke edilmiş melanomlu hastalarda adjuvan ortamda terapötik bir immün yanıtı indüklemek için tasarlanmış Faz 1/2a çalışmasında olan DNA bazlı bir aşı olan EVX-02'yi ve çeşitli kanserlerin tedavisi için DNA bazlı kanser aşısı olan EVX-03'ü geliştirmektedir. Programları ayrıca, elektif abdominal fıtık ameliyatı geçiren hastalarda S. aureus kaynaklı cilt ve yumuşak doku enfeksiyonlarının önlenmesi için EVX-B1; N. gonorrhoeae'nin neden olduğu hastalıkları hedeflemek için EVX-B2; bakteriyel patojene karşı güçlü humoral antikor ve hücresel bağışıklık yanıtı ortaya çıkarmak için EVX-B3 ve Sitomegalovirüsü hedeflemek için viral aşı ürün adayı EVX-V1'i içeren klinik öncesi aşamada olan bazı aşıları da içermektedir.

Evaxion Biotech A/S Temel Bilgiler Özeti

Evaxion Biotech'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
EVAX temel i̇stati̇sti̇kler
Piyasa değeri	US$14.45m
Kazançlar(TTM)	-US$11.46m
Gelir(TTM)	US$3.30m

4.4x

P/S Oranı

-1.3x

F/K Oranı

EVAX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
EVAX gelir tablosu (TTM)
Gelir	US$3.30m
Gelir Maliyeti	US$0
Brüt Kâr	US$3.30m
Diğer Giderler	US$14.76m
Kazançlar	-US$11.46m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.05
Brüt Marj	100.00%
Net Kâr Marjı	-347.83%
Borç/Özkaynak Oranı	0%

EVAX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

EVAX Stoklara Genel Bakış

Ödüller

Risk Analizi

Evaxion Biotech A/S Rakipler

NasdaqCM:BIAF

US$18.5m

NasdaqCM:ONCO

US$24.1m

NasdaqCM:TNXP

US$24.9m

NasdaqCM:ERNA

US$5.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Recent updates

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Negative shareholders equity

Evaxion Biotech A/S to Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source of Ai-Discovered Targets

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S Announces Encouraging Initial Phase 2 Clinical Data on its Personalised Cancer Vaccine EVX-01

New and Exciting Clinical Data on Evaxion's Ai-Immunology™?-Based Personalized Cancer Vaccines to Be Presented

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion Biotech A/S Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company

Evaxion Biotech A/S Announces New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S announced that it expects to receive $20 million in funding from Negma Group Investment Ltd

Evaxion Biotech A/S Plans to Announce the Interim Results of the Clinical Phase 2 Study with EVX-01 in Patients with Metastatic Melanoma in Fourth Quarter 2023

Evaxion Unveils Genetic Adjuvant Technology to Boost Vaccines

Forecast to breakeven in 2024

Evaxion Unveils Proprietary Genetic Aduvant Technology to Boost the Effect of Dna and Mrna Vaccines

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S and Pantherna Therapeutics GmbH Announce Promising Preclinical mRNA Vaccine Data

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives Phase IIb Go-Ahead from FDA

Evaxion Biotech A/S Receives Approval from FDA to Proceed with the Clinical Phase 2B Study for Evx-01

Evaxion Biotech Reaches an Important Milestone When Enrolled Its First Patient in Perth, Australia in the Company's Global Phase 2B Clinical Trial of EVX-01

Evaxion Biotech A/S Announces Promising Results from Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02

Price target decreased to US$14.67

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech A/S Enrols First Patient in Phase Iib Melanoma Study

Evaxion Biotech A/S Enrolls First Patient in the Global Phase 2B Clinical Trial of EVX-01

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Forecast to breakeven in 2024

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Evaxion Biotech A/S Announces Executive Management Changes

Evaxion Biotech announces new CEO as Lars Wegner resigns

Evaxion Biotech A/S Announces Gonorrhea as Second Bacterial Product Target

Evaxion Biotech Expands its EVX-03 DNA Vaccine Program into Non-Small Cell Lung Cancer

Evaxion Biotech A/S announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

Evaxion Biotech A/S Approves Election of Niels Iversen Møller as New Member of the Board of Directors

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2A Clinical Trial for EVX-02

Evaxion Biotech A/S, Annual General Meeting, May 03, 2022

Evaxion Biotech A/S Announces Executive Changes